High-yield 'mousetrap' REITs consistently underperform, with significant risk of dividend cuts and capital loss, as evidenced by recent 12-month returns lagging VNQ by over 1,000 bps. Dividend Safety scores are critical; REITs rated F face a 40% chance of a cut within 12 months, often resulting in sharp share price declines. Key danger signals include high payout ratios, weak revenues, and heavy debt loads.

Alexander's (NYSE: ALX - Get Free Report) and Four Corners Property Trust (NYSE: FCPT - Get Free Report) are both finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability. Volatility and Risk Alexander's has a beta

SG Americas Securities LLC grew its stake in Alexander's, Inc. (NYSE: ALX) by 962.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,952 shares of the real estate investment trust's stock after acquiring an additional 9,921 shares during

Indexes for US equity real estate investment trusts fell further alongside the broader stock market during the week ended March 13. The Dow Jones Equity All REIT index closed the recent week down 1.52%, while the S&P 500 and Dow Jones Industrial Average fell 1.60% and 1.99%, respectively. The healthcare REIT index was the only property sector index to rise and was up 1.17%.

U.S. equities slid to four-month lows as the escalating Iran war rattled markets, sending oil to three-year highs and interest rates higher amid tanker attacks, shipping disruptions, and intensifying strikes. Brent Crude jumped above $100 as attacks on shipping in the Strait of Hormuz and tanker explosions threatened global oil flows, fueling inflation fears and keeping investors on edge. The White House deployed emergency supply measures—including Russian crude purchases and potential strategic reserve releases—but markets remain skeptical they can offset disruptions to global energy flows.

Alexander's, Inc. (NYSE: ALX - Get Free Report) shares crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $230.09 and traded as high as $251.00. Alexander's shares last traded at $244.4490, with a volume of 69,183 shares changing hands. Analyst Ratings Changes A number of analysts

PARAMUS, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has entered into an agreement to sell its Rego Park I property to Northwell Health, Inc. The gross purchase price is $235.5 million and the net proceeds will be $202 million. The property is unencumbered.

Alexander's (NYSE: ALX - Get Free Report) and Rexford Industrial Realty (NYSE: REXR - Get Free Report) are both finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends. Earnings and Valuation This table compares Alexander's and

- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company anticipates multiple meaningful data sets and milestones in the coming 12 to 18 months - - Evorpacept biomarker strategy validated by data from both the Phase 2 ASPEN-06 gastric cancer trial and the Phase 1b/2 breast cancer trial, independently suggesting CD47 overexpression is predictive of evorpacept activity and drives durable benefit in HER2-positive cancers - - Full biomarker analysis from Phase 1b/2 evorpacept-zanidatamab combination trial accepted for poster presentation at ESMO Breast Cancer 2026 Annual Congress - - Phase 2 ASPEN-09 breast cancer trial is currently enrolling patients and will evaluate evorpacept efficacy by CD47 expression levels, with topline data anticipated mid-2027 - - Phase 1 trial evaluating ALX2004 continues to enroll patients in the third dose cohort; safety data from dose-escalation phase expected in 2H 2026 - - Company completed a $150 million registered offering of common stock and pre-funded warrants, extending cash runway through 1H 2028 inclusive of key clinical program milestones for evorpacept and ALX2004 - - Barbara Klencke, M.D., appointed to Chief Medical Officer on a permanent basis - - Company to host webcast on Friday, February 27, at 5:30 a.m.

Alexander's (ALX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.